poisar

Stocks · News reference

Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3

Jul 15, 2026, 11:53 AMBenzinga Newsdesk

Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new preclinical data independently

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ERNA
Source
benzinga
Observed
Jul 15, 2026, 11:53 AM
Checked
Jul 15, 2026, 11:53 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading